Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medical University of Vienna
The objectives of this study are to evaluate the effectivity and the safety of thalidomide in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation. It is a phase II prospective single arm study with a target sample size of 16 patients. Thalidomide is given orally at an initial dose of 100 mg for a maximum duration of 6 months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologically confirmed MALT lymphoma with measurable disease (Stage I-IV)
With first or greater relapse after HP-eradication, radiation or chemotherapy
Age \> 18
Must be able to tolerate therapy and have adequate cardiac, renal and hepatic function
ECOG status \_\< 2
Must be capable of understanding the purpose of the study and have given written informed consent
